You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)

 

Online download statistics by month:

Online download statistics by month: November 2020 to September 2024

AbstractFullPdf
Nov 2020130013
Dec 20202506
Jan 20211702
Feb 20213207
Mar 20215805
Apr 20214006
May 20212307
Jun 2021005
Jul 2021004
Aug 2021008
Sep 2021002
Oct 202134023
Nov 202141017
Dec 20214802
Jan 20223805
Feb 202260012
Mar 2022104010
Apr 20228408
May 2022104014
Jun 20228807
Jul 20229004
Aug 202214808
Sep 20225804
Oct 20227405
Nov 202210209
Dec 20228209
Jan 202317607
Feb 202388017
Mar 20235606
Apr 20234605
May 20233402
Jun 20236209
Jul 20233003
Aug 20232602
Sep 20233402
Oct 20234806
Nov 20235806
Dec 20235403
Jan 20244202
Feb 20244601
Mar 20242800
Apr 20243006
May 20241000
Jun 20242801
Jul 20241201
Aug 20242805
Sep 20242201
Total24380287